Mizuho Rates Assembly Biosciences (ASMB) buy, $45 Price Target
Mizuho reiterates its Buy rating on ASMB, aiming for a $45 target, a 95.99% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Mizuho rated Assembly Biosciences, Inc. ($ASMB) "buy" with a $45 price target on June 15, 2026.
Since the rating, $ASMB is up 7.8% after 1 week, up 14.5% after 1 month and down 13.9% to date (from the $23.34 close on Jun 15, 2026).
ASMB
Assembly Biosciences, Inc.
Key Points
- Mizuho reiterated its Buy rating on ASMB with a $45 price target on June 15, 2026.
- Mizuho's $45 price target implies 95.99% upside from Assembly Biosciences, Inc.'s ($ASMB) current $22.96 share price.
- ASMB shares are trading at $22.96, with recent insider buying activity noted.
- Peer funds like Janus Henderson increased their ASMB holdings, while other funds maintained their positions.
Get $ASMB trade alerts by text
We text you when insiders, Congress or big funds trade $ASMB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Assembly Biosciences, Inc. alert may contain errors. Disclosures
On June 15, 2026, Mizuho reiterated its Buy rating on ASMB, setting a price target of $45. Analyst Salim Syed emphasized confidence in the stock's potential, with ASMB currently trading at $22.96.
Other Institutional Activity in ASMB
Janus Henderson Group PLC increased its holdings in ASMB by 11,384 shares, ending with 849,309 shares valued at approximately $23.48 million. Meanwhile, other major funds like Gilead Sciences, Inc., Farallon Capital Management LLC, and RA Capital Management, L.P., held steady with their positions, maintaining their share counts at 4,505,391, 1,227,590, and 1,020,410 shares respectively.
Assembly Biosciences, Inc. Stock Down 8.0%
ASMB shares are currently trading at $22.96. The stock has seen various analyst activities, with a notable Buy rating and a target price of $45 from Mizuho. This reflects confidence from analysts and investors despite the current trading price.
$ASMB price target
Assembly Biosciences, Inc. daily closes and this analyst's $45 target. Not advice.
Insider Buying and Selling at Assembly Biosciences, Inc.
Several insiders, including John McHutchison, Susan Mahony, and Anthony Altig, each purchased 8,000 shares of ASMB on June 4, 2026. These transactions were not part of a pre-planned trading program, indicating personal confidence in the company's prospects.
Analysts Set New Price Targets
On June 15, 2026, Mizuho maintained its Buy rating on ASMB with a $45 price target. Earlier, on April 6, 2026, Guggenheim also maintained a Buy rating with a $43 target. Furthermore, HC Wainwright & Co. reiterated a Buy rating on March 26, 2026, with a higher target of $50. The consensus among analysts is a strong Buy recommendation.
About ASMB
ASMB operates in the biotechnology sector, focusing on developing innovative therapies for various diseases. The company is headquartered in the United States and works on advancing treatments that address unmet medical needs.
Bottom Line
Mizuho's reaffirmed Buy rating and $45 price target for ASMB highlight the firm's positive outlook on the stock. With ASMB trading at $22.96 and insider buying activity, there is interest in the company's future potential. It's important to remember that these analyst ratings and price targets are based on current data and can change over time.
Related Filing Alerts
Source: Mizuho's rating change on $ASMB (Jun 15, 2026). Written by software, not financial advice. How we make alerts